Premium
Instanyl: intranasal fentanyl for treating breakthrough pain
Author(s) -
Chaplin Steve,
Zeppetella Giovambattista
Publication year - 2010
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.602
Subject(s) - medicine , fentanyl , nasal administration , breakthrough pain , cancer pain , pain management , adverse effect , chronic pain , anesthesia , intensive care medicine , cancer , pharmacology , physical therapy
Instanyl is an intranasal formulation of fentanyl licensed for breakthrough pain management in chronic cancer pain. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects and Dr Giovambattista Zeppetella discusses its place in the management of breakthrough pain. Copyright © 2010 Wiley Interface Ltd